1. Pink Sheet
  2. >>R&D

US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

 
• By Michael Cipriano

Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.

Pink Sheet Perspectives 2017 - 2018

With a historic high of second half of breakthrough therapy designation awards, the US FDA has set another yearly record of designations, with the agency granting a total of 56 in 2017.

The breakthrough therapy program – which has been a source of pride and exhaustion for the agency – completed its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 
• By Neena Brizmohun

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.